Mar 28, 2023

Benjamin Lightburn, Co-Founder and CEO of Filament Health points out that up until now, research with psychedelics has been done with synthetically prepared psychedelic substances.  Filament is making a product through natural extraction that results in a medicine containing psilocybin plus over a dozen other active...

Mar 28, 2023

Benjamin Lightburn, Co-Founder and CEO of Filament Health points out that up until now, research with psychedelics has been done with synthetically prepared psychedelic substances.  Filament is making a product through natural extraction that results in a medicine containing psilocybin plus over a dozen other active...

Mar 21, 2023

David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components...

Mar 21, 2023

David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway leads to the activation of this inflammatory response in diseases with components...

Feb 28, 2023

Dr. Robert Risinger is the Chief Medical Officer for Neuroscience at BioXcel Therapeutics, identifying molecules that have off-target indications to address unmet neurological diseases. The initial focus is on acute agitation and the molecules that will address this agitation in patients with bipolar and schizophrenia. ...